Also trades as: 0QF.F (FSX) · $vol 6M
MRNA NASDAQ
Moderna, Inc.
1W: -14.1%
1M: +5.4%
3M: +281.7%
YTD: +395.8%
1Y: +724.0%
3Y: +81.5%
5Y: -51.4%
$207.97
+9.12 (+4.59%)
Pre-Market: $204.43 (-3.54, -1.70%)
Weekly Expected Move ±15.2%
$139
$170
$200
$231
$261
Credit Risk of going bust: higher than 68% of companies Debt: 1.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.44 (down 99.8%), Moderna, Inc. would be worth roughly what it owes.
Total debt $1.29B against a stock market value of $83.03B.
Distance to default 3.53 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $347.5M (short-term plus half of long-term), stock volatility 132.3%; Altman Z'' 3.29. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.44 (down 99.8%), Moderna, Inc. would be worth roughly what it owes.
Total debt $1.29B against a stock market value of $83.03B.
Distance to default 3.53 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $347.5M (short-term plus half of long-term), stock volatility 132.3%; Altman Z'' 3.29. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships2
As Filer
counterparties named
4
As Counterparty
mentioned by others
1
Rel. Types
2023-01-05
Earliest Filing
2026-03-23
Latest Filing
partner: 2
Counterparties (Filed by MRNA)
2 relationshipsCompanies named in MRNA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Arbutus Biopharma Corporation | ABUS | partner | Settlement agreement to resolve patent infringement litigation involving lump sum and contingent payments | 2026-03-05 | View |
| Genevant Sciences GmbH | — | partner | Joint entity with Arbutus Biopharma Corporation involved in patent infringement litigation settlement | 2026-03-05 | View |
Mentioned As Counterparty
4 mentionsOther companies that named MRNA in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| ROIV Roivant Sciences Ltd. | partner | Counterparty in patent litigation settlement regarding lipid nanoparticle technology. | 2026-03-23 | View |
| ROIV Roivant Sciences Ltd. | partner | Pharmaceutical company involved in patent litigation settlement and licensing agreement. | 2026-03-03 | View |
| ABUS Arbutus Biopharma Corp | target | Paid $2.25 billion global settlement to resolve patent infringement claims regarding LNP delivery technology used in COV | 2026-03-03 | View |
| CTMX CytomX Therapeutics, Inc. | partner | Parent company of ModernaTX, Inc., entered into a collaboration and license agreement for mRNA-based investigational the | 2023-01-05 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-30 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-09-01 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-07-31 | Earnings Release; Exhibits | View | |
| 2026-07-08 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-05-11 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-01 | Earnings Release; Exhibits | View | |
| 2026-03-05 | Entry into Material Definitive Agreement | Agreement | View |
| 2026-02-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-11 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-05 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-24 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-11-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-05 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR